Angelman Syndrome - 9 Studies Found

Completed : Assessment of the Pharmacokinetics of Circadin® in Children With Neurodevelopmental Disorders and Sleep Disturbances
: Sleep Problems
: 2013-07-16
:
  • Drug: Circadin 2 mg First arm

Completed : Genomic Imprinting and Assisted Reproductive Technologies
:
  • Natural Pregnancy
  • Pregnancy, Ovarian

: 2008-10-15
Withdrawn : An Exploratory Open Label Study of EPI-743 (Vincerinone TM) in Children With Autism Spectrum Disorder
: Autism Spectrum Disorder
: 2014-08-21
: Drug: EPI-743 Other Name: Vincerinone TM
Active, not recruiting : Efficacy and Safety of Circadin® in the Treatment of Sleep Disturbances in Children With Neurodevelopment Disabilities
: Sleep Disorders
: 2013-07-11
:
  • Drug: Circadin 2/5/10 mg Activ
COMPLETED : Development of a Newborn Screening Assay for Angelman Syndrome and Prader-Willi Syndrome
: Angelman Syndrome
: 2025-09-01
: The assay developed in this study is determined to be FDA regulated as an exempt diagnostic device.In this study, the testing involved with t
Completed : Study to Investigate the Pharmacokinetics and Safety and to Provide Proof of Mechanism of Alogabat in Children and Adolescents Aged 5-17 Years With Angelman Syndrome (AS) With Deletion Genotype.
: Angelman Syndrome
: 2025-09-01
: Participants aged 15-17 years or above receiving the adult 60 mg of alogabat dose.I
COMPLETED : An Open-Label Study of the Safety, Tolerability, and Pharmacokinetics of Oral NNZ-2591 in Angelman Syndrome
: Angelman Syndrome
: 2025-09-01
: NNZ-2591 oral solution (50mg/mL) to be administered twice daily for 13 weeks.
COMPLETED : A Study of the Safety and Tolerability of GTX-102 in Children with Angelman Syndrome
: Angelman Syndrome
: 2025-09-01
: antisense oligonucleotide
COMPLETED : A Study to Investigate the Safety, Tolerability, Pharmacokinetics (PK) and Pharmacodynamics (PD) of RO7248824 in Participants With Angelman Syndrome (AS)
: Angelman Syndrome
: 2025-09-01
: In the MAD part, RO7248824 will be administered as IT injection of varing dose levels over a period of 8 weeks, with a minimum of approximately 4 week